Cholesterol Metabolite 27-OHC Accelerates Brain Aging via Microglial Iron Overload
27-Hydroxycholesterol triggers microglial senescence through iron dysregulation, and the iron chelator deferoxamine reverses the damage.
Summary
A new study in NPJ Aging identifies a molecular chain linking elevated blood cholesterol to brain aging: the oxysterol 27-hydroxycholesterol (27-OHC) accumulates in the brain, overloads microglia with iron, triggers cellular senescence, and drives neuroinflammation. In 71 human subjects (27 healthy controls, 27 MCI, 17 AD patients), plasma 27-OHC levels were significantly elevated in MCI and AD and negatively correlated with cognitive test scores. Mouse experiments confirmed that 27-OHC impairs hippocampal-dependent memory. In microglial cell cultures, 27-OHC disrupted iron transport proteins, elevated reactive oxygen species, and impaired mitochondria. Crucially, deferoxamine — an FDA-approved iron chelator — reversed these effects, positioning the 27-OHC–iron axis as a tractable therapeutic target.
Detailed Summary
Brain aging is the single greatest risk factor for Alzheimer's disease (AD), yet the upstream metabolic drivers of microglial senescence remain poorly understood. This study from Ningxia Medical University proposes and tests a specific mechanistic chain: peripheral hypercholesterolemia elevates the oxysterol 27-hydroxycholesterol (27-OHC), which crosses the blood-brain barrier, accumulates in microglia, disrupts iron homeostasis, and thereby accelerates cellular senescence and neuroinflammation. The clinical leg of the study enrolled 71 participants — 27 age-matched healthy controls, 27 with mild cognitive impairment (MCI), and 17 with AD. Plasma 27-OHC was significantly elevated in both MCI and AD groups versus controls, while the neuroprotective oxysterol 24S-OHC was reduced. The ratio of 27-OHC to 24S-OHC was markedly higher in disease groups. Critically, 27-OHC levels showed a significant negative correlation with MMSE scores (r = −0.49, p = 0.045), and the Aβ42/Aβ40 ratio — a validated AD biomarker — was negatively correlated with both total cholesterol (r = −0.64, p = 0.005) and 27-OHC (r = −0.61, p = 0.006). Liver function markers AST and ALT were also elevated in MCI and AD, and AST/ALT ratio negatively correlated with MMSE (r = −0.56, p = 0.007), connecting peripheral metabolic dysfunction to central cognitive decline.
To establish causality, the authors administered 27-OHC (5 mg/kg, corresponding to human plasma concentrations of 800–1000 ng/mL observed in AD patients) to mice and performed a battery of cognitive and behavioral tests. In the Morris Water Maze, 27-OHC-treated mice required significantly more time to locate the escape platform and made fewer platform crossings in the probe trial. The Novel Object Recognition cognitive index and three-chamber social preference index were both markedly lower in 27-OHC-treated animals, indicating impairments in recognition memory and social cognition. These behavioral deficits were accompanied by elevated hippocampal expression of cellular senescence markers P21, P16, and SA-β-galactosidase (SA-β-Gal), along with M1 microglial polarization characterized by increased iNOS expression — consistent with a pro-inflammatory, senescent microglial state.
In BV-2 microglial cells, 27-OHC treatment disrupted key iron-handling proteins: DMT1 (divalent metal transporter 1, responsible for iron import) was upregulated while ferritin (iron storage) and GPX4 (glutathione peroxidase 4, a ferroptosis suppressor) were downregulated. This combination — more iron uptake, less storage buffering, less ferroptosis protection — produced measurable iron overload, elevated reactive oxygen species (ROS), and impaired mitochondrial membrane potential. Together these changes constitute a ferroptosis-prone, senescent microglial phenotype. Deferoxamine (DFX), an iron chelator already approved and used clinically, reversed the 27-OHC-induced dysregulation of DMT1, ferritin, and GPX4, reduced ROS accumulation, restored mitochondrial function, and significantly attenuated markers of microglial senescence and M1 polarization in vitro.
The study's translational significance is substantial. It draws a direct line from a well-known metabolic risk factor — elevated circulating cholesterol — through a specific lipid metabolite (27-OHC) to a concrete cellular mechanism (iron-dependent microglial senescence) and to an already-approved therapeutic agent (deferoxamine). The 27-OHC–iron axis represents a novel mechanistic node linking hypercholesterolemia, iron dyshomeostasis, microglial aging, and neuroinflammation. This framework may explain a portion of why cardiovascular and metabolic risk factors increase dementia risk, and suggests that iron chelation therapy or strategies to reduce 27-OHC accumulation in the brain could be worth evaluating in early-stage AD or MCI clinical trials.
Several caveats temper interpretation. The clinical cohort is small (n = 71), cross-sectional, and correlational — causality in humans cannot be established from these data. The in vivo mouse model uses exogenous 27-OHC administration rather than a genetic hypercholesterolemia model, and the in vitro BV-2 cell line does not fully recapitulate primary human microglia behavior. The paper does not report long-term safety or efficacy data for DFX in a neurological context, and the specific iron transport pathway from the periphery to the microglial compartment is not fully delineated. Nonetheless, the convergence of clinical correlation data, animal behavioral phenotyping, and mechanistic cell biology provides a coherent and testable framework for future intervention studies.
Key Findings
- Plasma 27-OHC was significantly elevated in MCI and AD patients versus controls and negatively correlated with MMSE cognitive scores (r = −0.49, p = 0.045)
- The Aβ42/Aβ40 ratio was negatively correlated with 27-OHC (r = −0.61, p = 0.006) and positively correlated with neuroprotective 24S-OHC (r = 0.70, p < 0.02)
- Mice injected with 27-OHC (5 mg/kg) showed significantly impaired Morris Water Maze performance, reduced Novel Object Recognition indices, and lower social preference scores versus controls
- 27-OHC-treated mice exhibited elevated hippocampal senescence markers P21, P16, and SA-β-Gal alongside M1 microglial polarization (increased iNOS)
- In BV-2 microglia, 27-OHC upregulated iron importer DMT1 while downregulating ferritin and GPX4, producing iron overload, elevated ROS, and mitochondrial dysfunction consistent with ferroptosis vulnerability
- Deferoxamine (DFX) reversed 27-OHC-induced iron dysregulation, restored GPX4 and ferritin expression, reduced ROS, and attenuated microglial senescence markers in vitro
- AST/ALT ratio (liver dysfunction marker) negatively correlated with MMSE scores in AD/MCI patients (r = −0.56, p = 0.007), linking peripheral metabolic disease to cognitive decline
Methodology
The study combined a cross-sectional clinical cohort (n = 71: 27 controls, 27 MCI, 17 AD patients) with in vivo mouse behavioral experiments (27-OHC 5 mg/kg administration) and in vitro BV-2 microglial cell culture assays. Clinical measurements included plasma ELISA for 27-OHC, 24S-OHC, Aβ40, and Aβ42, plus liver enzymes and total cholesterol, with Pearson correlations to MMSE scores. In vivo cognitive assessments used Morris Water Maze, Novel Object Recognition, and three-chamber social interaction tests. In vitro analyses included Western blotting for senescence (P21, P16) and iron-metabolism proteins (DMT1, ferritin, GPX4), SA-β-Gal staining, ROS quantification, and mitochondrial membrane potential assays. Statistical comparisons used one-way ANOVA with post-hoc testing; p < 0.05 was the significance threshold.
Study Limitations
The clinical cohort is small (n = 71) and cross-sectional, precluding causal inference in humans, and the AD group had lower education levels which may confound MMSE comparisons. The animal model relies on exogenous 27-OHC injection rather than a physiological hypercholesterolemic model, and all mechanistic cell work uses the BV-2 immortalized mouse microglial line rather than primary human microglia. No conflicts of interest were disclosed by the authors.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.